Search the Newsreel

Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next

Novartis is celebrating its 30th anniversary, reflecting on a 250-year legacy of scientific discovery rooted in the merger of Ciba-Geigy and Sandoz. The company has pioneered significant medical advancements, including targeted cancer therapies, cell therapy, and gene therapy, continually pushing the boundaries of what …

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis announced that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of disease progression. This approval, following an earlier accelerated approval, is based on data showing Fabhalta significantly slowed …

Earnings Preview: Novartis AG to Report Financial Results on July 21

Novartis AG (NYSE:NVS) is scheduled to announce its quarterly earnings results on Friday, July 21st. The company has a history of meeting or beating analyst estimates and currently has a consensus EPS estimate of $1.76 and a revenue estimate of $13.56 billion for the …

Novartis stock holds steady on its global drug pipeline

Novartis's stock remains stable, supported by its global drug pipeline and status as a major European drugmaker. The company's focus on innovative medicines across oncology, immunology, cardiovascular disease, and neuroscience provides a strong foundation for its recurring specialty-drug revenue and resilience in the market. …

Novartis’s 18.3M-share rebound keeps its 63-week Trend Signal intact, but pressure is still negative

Novartis outpaced its drugmaker group for the week on heavy volume, yet the broader confirmation picture is mixed as Market Dynamics remains below zero.

Be Sure To Check Out Novus Holdings Limited (JSE:NVS) Before It Goes Ex-Dividend

Novartis AG ADR (NVS) preferred-stock disposal record meets firmer weekly tape

The insider-activity item is historical, while current market data show the healthcare ADR rising across recent weekly horizons with some pressure still present.

Novus Holdings Limited (JSE:NVS) Doing What It Can To Lift Shares